Search results
Results From The WOW.Com Content Network
The newest weight loss medication, Wegovy (Semaglutide) came on the market in June 2021 and demand for the medication has been high. This medication, a once weekly injection, had excellent results in clinical trials showing weight loss of up to 15% body weight.
The FDA approved Wegovy, a weight management medication, to lower the risk of heart attack, stroke, and other cardiovascular problems in adults with heart disease who are overweight or who have obesity. Learn why this approval has pros and cons.
Wegovy is a once-weekly injectable prescription medicine recently FDA-approved to help adults with obesity—or excess weight along with weight-related medical problems—lose weight.
You may be more familiar with the common brand names of this drug, Ozempic and Wegovy. This medication, initially approved as a new option for the management of type 2 diabetes (Ozempic), gained significant attention for its weight-loss benefits, which led to the approval of Wegovy.
Wegovy acts on areas of the brain which are involved in regulating your appetite. It increases feelings of fullness, reduces feelings of hunger and reduces the preference for high-fat foods. It also reduces blood sugar by promoting the release of insulin when blood sugar levels are high.
Is Wegovy effective for weight loss? Given Wegovy is a semaglutide, there is very strong evidence it can help people lose weight and maintain this weight loss.
A new analysis shows that Wegovy is effective for long-term weight loss, with users maintaining weight loss for at least four years. The medication shows significant cardiovascular benefits and appears to reduce the risk of heart disease independently of weight loss.